<![CDATA[Year in Review: FDA Expands Biosimilar Approvals Across Oncology, Immunology, and Bone Health]]>
In 2025, the FDA continued its expansion of the US biosimilar landscape, with recent approvals spanning osteoporosis, oncology, immunology, rheumatology, and ophthalmology, reflecting growing confidence in biosimilars as safe, effective, and more …